Talkspace (TALK) Revenue & Revenue Breakdown
Talkspace Revenue Highlights
Latest Revenue (Y)
$187.59M
Latest Revenue (Q)
$59.38M
Talkspace Revenue by Period
Talkspace Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $187.59M | 25.02% |
| 2023-12-31 | $150.04M | 25.49% |
| 2022-12-31 | $119.57M | 5.19% |
| 2021-12-31 | $113.67M | 49.19% |
| 2020-12-31 | $76.19M | 99.57% |
| 2019-12-31 | $38.18M | - |
Talkspace generated $187.59M in revenue during NA 2024, up 25.02% compared to the previous quarter, and up 491.36% compared to the same period a year ago.
Talkspace Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $59.38M | 9.34% |
| 2025-06-30 | $54.31M | 4.08% |
| 2025-03-31 | $52.18M | 7.11% |
| 2024-12-31 | $48.72M | 2.79% |
| 2024-09-30 | $47.40M | 2.91% |
| 2024-06-30 | $46.06M | 1.41% |
| 2024-03-31 | $45.42M | 7.07% |
| 2023-12-31 | $42.42M | 9.76% |
| 2023-09-30 | $38.65M | 8.42% |
| 2023-06-30 | $35.65M | 6.93% |
| 2023-03-31 | $33.34M | 10.23% |
| 2022-12-31 | $30.24M | 3.10% |
| 2022-09-30 | $29.33M | -1.72% |
| 2022-06-30 | $29.84M | -1.01% |
| 2022-03-31 | $30.15M | 3.35% |
| 2021-12-31 | $29.17M | 10.67% |
| 2021-09-30 | $26.36M | -14.92% |
| 2021-06-30 | $30.98M | 14.09% |
| 2021-03-31 | $27.16M | 5.72% |
| 2020-12-31 | $25.69M | 19.45% |
| 2020-09-30 | $21.50M | 20.29% |
| 2020-06-30 | $17.88M | 100.00% |
| 2020-03-31 | - | - |
Talkspace generated $59.38M in revenue during Q3 2025, up 9.34% compared to the previous quarter, and up 128.93% compared to the same period a year ago.
Talkspace Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CYH | Community Health Systems | $12.63B | $3.09B |
| INNV | InnovAge | $853.70M | $236.10M |
| AVNS | Avanos Medical | $687.80M | $177.80M |
| SNDA | Sonida Senior Living | $304.33M | $98.04M |
| TALK | Talkspace | $187.59M | $59.38M |
| AIRS | AirSculpt | $180.35M | $34.99M |
| RIGL | Rigel Pharmaceuticals | $179.28M | $69.46M |
| CLPT | ClearPoint Neuro | $31.39M | $8.86M |
| NNNN | Anbio Biotechnology Class A Ordinary Shares | $8.19M | $2.53M |
| KALV | KalVista Pharmaceuticals | - | $13.69M |
| CMPS | COMPASS Pathways | - | - |